{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T12:10:18Z","timestamp":1775995818640,"version":"3.50.1"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Mutations commonly associated with acute myeloid leukemia (AML), such as CEBPA, FLT3, IDH1\/2, and NPM1, are rarely found in chronic myelomonocytic leukemia (CMML), and their prognostic significance in CMML has not been clearly identified. In 127 patients with CMML, we have retrospectively analyzed next-generation sequencing and polymerase chain reaction data from bone marrow samples collected at the time of CMML diagnosis. Seven patients harbored CEBPA mutations, 8 FLT3 mutations, 12 IDH1 mutations, 26 IDH2 mutations, and 11 NPM1 mutations. Patients with CMML harboring CEBPA, FLT3, and\/or NPM1 mutations (mutCFN) more frequently had the myeloproliferative subtype, a high prevalence of severe cytopenia, and elevated blast counts. Regardless of their CMML Prognostic Scoring System molecular classification, mutCFN patients with CMML had a poor prognosis, and the multivariate analysis identified mutCFN as an independent marker of overall survival. The genetic profile of these mutCFN patients with CMML closely resembled that of patients with AML, with higher-risk clinical characteristics. Our findings lead us to suggest including the assessment of these mutations in CMML prognostic models and treating these patients with AML-type therapies, including intensive chemotherapy and allogeneic stem cell transplantation, whenever feasible. Furthermore, certain targeted therapies approved for use in AML should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013648","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T20:00:55Z","timestamp":1728590455000},"page":"39-53","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["AML typical mutations (<i>CEBPA<\/i>, <i>FLT3<\/i>, <i>NPM1<\/i>) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-4665","authenticated-orcid":false,"given":"Sandra","family":"Casta\u00f1o-D\u00edez","sequence":"first","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f2nica","family":"L\u00f3pez-Guerra","sequence":"additional","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"3Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Zugasti","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Calvo","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"5Department of Hematology, Hospital del Mar, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicitas Isabel","family":"Schulz","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Avenda\u00f1o","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"7Department of Hematology, Hospital Universitario de Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-8803","authenticated-orcid":false,"given":"Elvira","family":"Mora","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"8Department of Hematology, Hospital Universitario y Polit\u00e9cnico la Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Falantes","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"9Department of Hematology, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-7355","authenticated-orcid":false,"given":"Gemma","family":"Azaceta","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"10Department of Hematology, Hospital Cl\u00ednico Universitario Lozano Blesa de Zaragoza, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"11Department of Hematology, Hospital General Universitario de Valencia, grupo de Investigaci\u00f3n de Hematolog\u00eda y Hemoterapia de la Fundaci\u00f3n de Investigaci\u00f3n del Hospital General Universitario de Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-8640","authenticated-orcid":false,"given":"Tzu","family":"Chen","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"12Department of Hematology, Hospital General Universitario Morales Meseguer, Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Notario","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"13Department of Hematology, Hospital Universitario Nuestra Se\u00f1ora de la Candelaria, Santa Cruz de Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-9272","authenticated-orcid":false,"given":"Neus","family":"Amer","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"14Department of Hematology, Hospital Universitario Son Ll\u00e0tzer, Palma de Mallorca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3176-6271","authenticated-orcid":false,"given":"Laura","family":"Palomo","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"15Department of Hematology, Experimental Hematology Group, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain. Myelodysplastic Syndromes Research Group, Josep Carreras Leukaemia Research Institute, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Pomares","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"16Department of Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran i Reynals, L'Hospitalet de LLobregat, LLobregat, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge, Universitat de Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"17Department of Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Dr. Josep Trueta, Girona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-513X","authenticated-orcid":false,"given":"Teresa","family":"Bernal del Castillo","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"18Department of Hematology, Hospital Central de Asturias, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Instituto Universitario de Oncolog\u00eda del Principado de Asturias, Oviedo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9548-4305","authenticated-orcid":false,"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Esteban","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Hospital Universitari Germans Trias i Pujol, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras, Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-0929","authenticated-orcid":false,"given":"Francesca","family":"Guijarro","sequence":"additional","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8579-082X","authenticated-orcid":false,"given":"Jos\u00e9","family":"\u00c1lamo","sequence":"additional","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-901X","authenticated-orcid":false,"given":"Albert","family":"Cort\u00e9s-Bullich","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Torrecillas-Mayayo","sequence":"additional","affiliation":[{"name":"20University of Barcelona, Faculty of Medicine, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Triguero","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Mont-de Torres","sequence":"additional","affiliation":[{"name":"20University of Barcelona, Faculty of Medicine, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Carcelero","sequence":"additional","affiliation":[{"name":"21Department of Pharmacy, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aina","family":"Card\u00fas","sequence":"additional","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Betz","sequence":"additional","affiliation":[{"name":"22Institute for Human Genetics, Medical Faculty and University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rozman","sequence":"additional","affiliation":[{"name":"1Department of Hematopathology, Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"},{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Arenillas","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"5Department of Hematology, Hospital del Mar, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Zamora","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"19Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Hospital Universitari Germans Trias i Pujol, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras, Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Mar\u00eda","family":"D\u00edez-Campelo","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"7Department of Hematology, Hospital Universitario de Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-1307","authenticated-orcid":false,"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"19Department of Hematology, Institut Catal\u00e0 d\u2019Oncologia-Hospital Universitari Germans Trias i Pujol, Institut de Recerca contra la Leuc\u00e8mia Josep Carreras, Badalona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8056-648X","authenticated-orcid":false,"given":"Jordi","family":"Esteve","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[{"name":"2Grupo Espa\u00f1ol de S\u00edndromes Mielodispl\u00e1sicos, Madrid, Spain"},{"name":"4Department of Hematology, Hospital Cl\u00ednic de Barcelona, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"issue":"2","key":"2025011415264482400_bib1","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"issue":"6","key":"2025011415264482400_bib2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s12185-017-2243-z","article-title":"CMML: clinical and molecular aspects","volume":"105","author":"Itzykson","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"2025011415264482400_bib3","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1097\/HS9.0000000000000150","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemias in adults: recommendations from the European Hematology Association and the European LeukemiaNet","volume":"2","author":"Itzykson","year":"2018","journal-title":"Hemasphere"},{"issue":"10","key":"2025011415264482400_bib4","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2025011415264482400_bib5","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/s41375-023-01964-3","article-title":"Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)","volume":"37","author":"Gurney","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025011415264482400_bib6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/ejh.12549","article-title":"Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation","volume":"96","author":"Peng","year":"2016","journal-title":"Eur J Haematol"},{"issue":"10","key":"2025011415264482400_bib7","doi-asserted-by":"crossref","first-page":"E614","DOI":"10.1002\/ajh.24861","article-title":"Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"92","author":"Vallapureddy","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2025011415264482400_bib8","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/bloodadvances.2018026989","article-title":"NPM1 mutations define a specific subgroup of MDS and MDS\/MPN patients with favorable outcomes with intensive chemotherapy","volume":"3","author":"Montalban-Bravo","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2025011415264482400_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.19060","article-title":"Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia","volume":"203","author":"Montalban-Bravo","year":"2023","journal-title":"Br J Haematol"},{"issue":"9","key":"2025011415264482400_bib10","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s12094-021-02585-x","article-title":"Mutations in chronic myelomonocytic leukemia and their prognostic relevance","volume":"23","author":"Jian","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"2025011415264482400_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.23345","article-title":"FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"88","author":"Daver","year":"2013","journal-title":"Am J Hematol"},{"issue":"1","key":"2025011415264482400_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.25684","article-title":"Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management","volume":"95","author":"Patnaik","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"2025011415264482400_bib13","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"DiNardo","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"2025011415264482400_bib14","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/leu.2010.52","article-title":"Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS\/myeloproliferative neoplasms","volume":"24","author":"Kosmider","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2025011415264482400_bib15","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41375-022-01551-y","article-title":"Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia","volume":"36","author":"Walsh","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2025011415264482400_bib16","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ajh.26455","article-title":"Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Patnaik","year":"2022","journal-title":"Am J Hematol"},{"key":"2025011415264482400_bib17","doi-asserted-by":"crossref","first-page":"106190","DOI":"10.1016\/j.leukres.2019.106190","article-title":"Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia","volume":"84","author":"Hwang","year":"2019","journal-title":"Leuk Res"},{"issue":"6","key":"2025011415264482400_bib18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2006.06081.x","article-title":"C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders","volume":"133","author":"Caudill","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"2025011415264482400_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/modpathol.2012.218","article-title":"Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia","volume":"26","author":"Courville","year":"2013","journal-title":"Mod Pathol"},{"issue":"11","key":"2025011415264482400_bib20","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.3109\/10428194.2015.1026900","article-title":"NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"56","author":"Forghieri","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2025011415264482400_bib21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3324\/haematol.2010.021808","article-title":"Transcription factor mutations in myelodysplastic\/myeloproliferative neoplasms","volume":"95","author":"Ernst","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"2025011415264482400_bib22","first-page":"1147","article-title":"Mutations and promoter methylation status of NPM1 in myeloproliferative disorders","volume":"91","author":"Oki","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"2025011415264482400_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-022-00284-z","article-title":"Mutational landscape of chronic myelomonocytic leukemia in Chinese patients","volume":"11","author":"Nie","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"2025011415264482400_bib24","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","article-title":"Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms","volume":"3","author":"Patel","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2025011415264482400_bib25","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/ijms21238975","article-title":"NPM1-mutated myeloid neoplasms with &lt;20% blasts: a really distinct clinico-pathologic entity?","volume":"21","author":"Forghieri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025011415264482400_bib26","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00428-022-03465-7","article-title":"Advances in myelodysplastic\/myeloproliferative neoplasms","volume":"482","author":"Prakash","year":"2023","journal-title":"Virchows Arch"},{"key":"2025011415264482400_bib27","doi-asserted-by":"crossref","first-page":"2040620719854596","DOI":"10.1177\/2040620719854596","article-title":"Chronic myelomonocytic leukemia associated with myeloid sarcomas and NPM1 mutation: a case report and literature review","volume":"10","author":"Matanes","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"2025011415264482400_bib28","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: new pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"issue":"7","key":"2025011415264482400_bib29","doi-asserted-by":"crossref","first-page":"20230429","DOI":"10.1002\/ajh.26946","article-title":"The NPM1 mutant defines AML irrespective of blast count","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"2025011415264482400_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.pathol.2022.10.009","article-title":"Acute myeloid leukaemia with NPM1 mutation: no longer having an absolute blast (count)","volume":"55","author":"Zhang","year":"2023","journal-title":"Pathology"},{"issue":"3","key":"2025011415264482400_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2025011415264482400_bib32","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/cncr.34119","article-title":"Time to blur the blast boundaries","volume":"128","author":"DiNardo","year":"2022","journal-title":"Cancer"},{"issue":"7","key":"2025011415264482400_bib33","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"2025011415264482400_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11912-019-0855-6","article-title":"Chronic myelomonocytic leukemia: insights into biology, prognostic factors, and treatment","volume":"21","author":"Coltro","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"19","key":"2025011415264482400_bib35","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025011415264482400_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11899-021-00643-3","article-title":"Management and outcomes of blast transformed chronic myelomonocytic leukemia","volume":"16","author":"Hammond","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"2025011415264482400_bib37","first-page":"9932837","article-title":"FLT3 amplification as double minute chromosomes in a patient with chronic myelomonocytic leukemia","volume":"2021","author":"Zhang","year":"2021","journal-title":"Dis Markers"},{"issue":"4","key":"2025011415264482400_bib38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14728214.2020.1854224","article-title":"Emerging drugs for the treatment of chronic myelomonocytic leukemia","volume":"25","author":"Ramos Perez","year":"2020","journal-title":"Expert Opin Emerg Drugs"},{"issue":"11","key":"2025011415264482400_bib39","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/15384047.2017.1281491","article-title":"Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib","volume":"18","author":"Gu","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"2025011415264482400_bib40","first-page":"82","author":"Swerdlow","year":"2017","edition":"Revised 4th ed."},{"issue":"7","key":"2025011415264482400_bib41","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025011415264482400_bib42","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2023-187676","article-title":"NPM1-mutated myeloid neoplasms: updated outcomes with high-intensive chemotherapy regardless of the blast percentage","volume":"142","author":"Gener-Ricos","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2025011415264482400_bib43","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.3390\/cancers14174107","article-title":"Real-world data on chronic myelomonocytic leukemia: clinical and molecular characteristics, treatment, emerging drugs, and patient outcomes","volume":"14","author":"Casta\u00f1o-D\u00edez","year":"2022","journal-title":"Cancers"},{"key":"2025011415264482400_bib44","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.3390\/cancers15153822","article-title":"Mutational profile enables the identification of a high-risk subgroup in myelodysplastic syndromes with isolated trisomy 8","volume":"15","author":"Toribio-Castello","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"2025011415264482400_bib45","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3324\/haematol.2020.248807","article-title":"Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia","volume":"106","author":"Martin-Izquierdo","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"2025011415264482400_bib46","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"14","key":"2025011415264482400_bib47","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025011415264482400_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"446","key":"2025011415264482400_bib49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"15","key":"2025011415264482400_bib50","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2025011415264482400_bib51","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2025011415264482400_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2025011415264482400_bib53","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1002\/hem3.123","article-title":"Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: results of the AML Study Group (AMLSG)","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"HemaSphere"},{"issue":"9","key":"2025011415264482400_bib54","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1182\/bloodadvances.2022008204","article-title":"CNL and aCML should be considered as a single entity based on molecular profiles and outcomes","volume":"7","author":"Carre\u00f1o-Tarragona","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2025011415264482400_bib55","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"2025011415264482400_bib56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2007.08.031","article-title":"FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia","volume":"12","author":"Lee","year":"2007","journal-title":"Cancer Cell"},{"issue":"9","key":"2025011415264482400_bib57","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41375-022-01650-w","article-title":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial","volume":"36","author":"Jahn","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2025011415264482400_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.stemcr.2020.05.002","article-title":"Driver mutations in leukemia promote disease pathogenesis through a combination of cell-autonomous and niche modulation","volume":"15","author":"Ramdas","year":"2020","journal-title":"Stem Cell Rep"},{"issue":"4","key":"2025011415264482400_bib59","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2025011415264482400_bib60","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025011415264482400_bib61","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2021-150786","article-title":"Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia","volume":"138","author":"Walsh","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2025011415264482400_bib62","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2025011415264482400_bib63","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2022-167138","article-title":"Machine learning allows the identification of new co-mutational patterns with prognostic implications in NPM1 mutated AML - results of the European Harmony Alliance","volume":"140","author":"Hern\u00e1ndez S\u00e1nchez","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/39\/2349579\/blooda_adv-2024-013648-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/1\/39\/2349579\/blooda_adv-2024-013648-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T15:52:04Z","timestamp":1736869924000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/1\/39\/518150\/AML-typical-mutations-CEBPA-FLT3-NPM1-identify-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013648","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}